Rejoint® YourKnee™ received CE Mark Approval

MILAN, January 16, 2020 — Rejoint, provider of “Patient Specific” 3D Printed Total Knee Replacements that enhance clinical outcomes, announced today that it has received Conformité Européene (CE) Mark approval for YourKnee.

The CE marking confirms that YourKnee meets the requirements of the European Medical Devices Directive, which now allows Rejoint to commercialize YourKnee and its disposable products across the European Union and other CE Mark geographies.

Rejoint YourKnee is a “Patient Specific” holistic solution that provides personalized knee replacement and surgery recovery follow-up through the analysis of the patient’s anatomy, the implant design and surgery simulation based on anatomy data and thanks to the Artificial Intelligence outcomes. Through the production of a “Patient Specific” implant by the last generation of 3D printing technology reducing patient pain, speeding up the recovery with a competitive price.

Through the delivery of “Patient Specific” and “Computer Assisted” surgical tools for a personalized surgery together with an integrated system of dedicated wearables to monitor and to track remotely the surgery recovery and patient rehabilitation.

Gian Guido Riva, Co-Founder and CEO of Rejoint, said, “We are thrilled to be able to bring the power of personalization in orthopedics to the market. We have long been dedicated to helping improve the lives of patients suffering from knee pain bettering their quality of life. We look forward to witnessing the impact that YourKnee will now be able to have on current generations of patients giving a nod to the healthcare costs reduction”

About Rejoint

Rejoint is a start-up pioneer in new technology and surgical approaches in Total Knee Arthroplasty. Rejoint has developed a solution for knee replacement based on the integration of 3D Additive Manufacturing (AM), Artificial Intelligence (AI), and Internet of Things (IoT), which enables the design of personalized implants and surgical simulation based on unique patient anatomy. The company is led by people with more than 20 years in the orthopedic industry and by previous members of worldwide leading medtech companies like Covidien, Smith & Nephew, Sorin, Bellco.

Media Contact:

Gian Guido Riva
Rejoint Founder & CEO

About Peter Coffaro 506 Articles
Peter Coffaro is a growth-driven and strategic executive with over 25 years of progressive management success in the medical device industry. With a proven track record and recognized expertise, Peter has established himself as one of the top influencers in medical sales, as acknowledged by prestigious publications such as the World Journal of Orthopedics, Exponential Healthtech, and MedReps.com. Throughout his career, Peter has accumulated 10 years of combined sales management experience, excelling in various roles including Director, General Manager, Distributor, and Vice President. He has worked for industry-leading orthopedic companies such as Zimmer, DePuy, and Stryker, solidifying his deep knowledge and network within the field. Peter’s passion for innovation and emerging technologies led him to found OrthoFeed, an award-winning blog covering digital orthopedic news and emerging medical technologies. Through this platform, he stays at the forefront of the industry and contributes to the dissemination of valuable insights. Peter is a three-time Hall of Fame award winner at Johnson and Johnson, demonstrating his exceptional contributions and impact on the organization. His expertise extends to areas such as organizational development, business development, sales management, digital marketing, and professional education. Peter earned a B.S. degree in Biology and Chemistry from Northern Illinois University, further complementing his comprehensive understanding of the medical field. With his wealth of experience, strategic mindset, and dedication to advancing healthcare, Peter Coffaro is a valuable asset and leader in the medical device industry.

Be the first to comment

Leave a Reply

Your email address will not be published.


*


This site uses Akismet to reduce spam. Learn how your comment data is processed.